Publicaciones en colaboración con investigadores/as de University of Oslo (13)

2023

  1. Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?

    European heart journal. Cardiovascular pharmacotherapy, Vol. 9, Núm. 6, pp. 570-582

2022

  1. Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 2, pp. 187-210

  2. Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 8, Núm. 3, pp. 302-310

2021

  1. The age of randomized clinical trials: Three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 7, Núm. 5, pp. 453-459

  2. Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: A review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 7, Núm. 6, pp. 557-567

2018

  1. Antiarrhythmic drugs-clinical use and clinical decision making: A consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP)

    Europace, Vol. 20, Núm. 5, pp. 731-732

  2. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 4, Núm. 3, pp. 180-188

  3. Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

    European Heart Journal, Vol. 39, Núm. 24, pp. 2274-2281

  4. Reasons for disparity in statin adherence rates between clinical trials and real-world observations: A review

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 4, Núm. 4, pp. 230-236

2017

  1. Reversal strategies for non-Vitamin K antagonist oral anticoagulants: A critical appraisal of available evidence and recommendations for clinical management - A joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis

    European Heart Journal, Vol. 38, Núm. 22, pp. 1710-1716

2016

  1. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: Review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 2, Núm. 2, pp. 108-118

  2. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: Review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology

    European Heart Journal

2013

  1. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)

    European Heart Journal, Vol. 34, Núm. 28, pp. 2159-2219